Armstrong Fleming & Moore Inc Sells 8,366 Shares of Johnson & Johnson (NYSE:JNJ)

Armstrong Fleming & Moore Inc decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 68.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,915 shares of the company's stock after selling 8,366 shares during the quarter. Johnson & Johnson accounts for about 0.8% of Armstrong Fleming & Moore Inc's portfolio, making the stock its 28th largest holding. Armstrong Fleming & Moore Inc's holdings in Johnson & Johnson were worth $649,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Vest Financial LLC raised its stake in Johnson & Johnson by 10.7% in the 1st quarter. Vest Financial LLC now owns 405,364 shares of the company's stock worth $67,226,000 after purchasing an additional 39,217 shares in the last quarter. Annex Advisory Services LLC raised its stake in Johnson & Johnson by 5.5% in the 1st quarter. Annex Advisory Services LLC now owns 33,438 shares of the company's stock worth $5,545,000 after purchasing an additional 1,735 shares in the last quarter. Oak Asset Management LLC raised its stake in Johnson & Johnson by 0.8% in the 1st quarter. Oak Asset Management LLC now owns 26,385 shares of the company's stock worth $4,376,000 after purchasing an additional 220 shares in the last quarter. Retirement Planning Group LLC raised its stake in Johnson & Johnson by 6.7% in the 1st quarter. Retirement Planning Group LLC now owns 6,058 shares of the company's stock worth $1,005,000 after purchasing an additional 381 shares in the last quarter. Finally, Charles Schwab Trust Co raised its position in shares of Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Trust Co now owns 15,182 shares of the company's stock valued at $2,518,000 after buying an additional 282 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.9%

JNJ traded up $1.36 during trading on Friday, reaching $155.02. 5,387,625 shares of the company's stock were exchanged, compared to its average volume of 7,938,697. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $372.99 billion, a PE ratio of 23.31, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The firm has a fifty day moving average price of $153.59 and a two-hundred day moving average price of $153.68.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Barclays dropped their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday. Finally, Morgan Stanley boosted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.